Simlandi in Pakistan
How patients in Pakistan access Simlandi (adalimumab‑ryvk biosimilar) via Named Patient Program.
Simlandi - overview
Simlandi (adalimumab‑ryvk biosimilar) is manufactured by Alvotech / Teva and indicated for the full Humira-labeled indications, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis. It is a subcutaneous TNF-alpha inhibitor (high-concentration, citrate-free) approved by the US FDA in 2024 and may be accessible to patients in Pakistan through a Named Patient Program or personal-import pathway.
Access in Pakistan
Pakistan's DRAP permits personal-use import of unregistered specialty drugs; documentation-heavy process.
How Reserve Meds coordinates access in Pakistan
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Pakistan-specific eligibility.
- Treating physician in Pakistan issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Simlandi from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Pakistan.
Typical timeline for Pakistan
End-to-end, most requests are completed in 2-6 weeks. Pakistan's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Pakistan ask
- Is the pathway legal in Pakistan? Yes - it operates under Pakistan's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Pakistan able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.